Acute Myeloid Leukemia Coverage From Every Angle
Advertisement
Advertisement

Curtis Lachowiez, MD, on Clinical Implications of Using Venetoclax Plus FLAG-IDA in AML

Posted: Wednesday, September 15, 2021

Curtis Lachowiez, MD, of The University of Texas MD Anderson Cancer Center, offers clinical pearls on the use of venetoclax combined with FLAG-IDA chemotherapy in patients with newly diagnosed acute myeloid leukemia, including the best candidates for this regimen, how well it is tolerated, and how best to manage adverse effects.



By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.